Business Context and Reporting Period
This Form 8-K was filed by Aeglea BioTherapeutics, Inc. (trading symbol: AGLE) on July 13, 2023. The filing addresses a change in the listing status of the Company's common stock on The Nasdaq Stock Market. Note: The request metadata references "Spyre Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Aeglea BioTherapeutics, Inc.
Key Financial Metrics
This filing is a current report regarding listing status and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Listing Transfer: The Company's common stock was transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective July 14, 2023.
- Reason for Transfer: The transfer was necessitated by the Company's failure to meet the Minimum Bid Price Requirement ($1.00 per share) for 30 consecutive trading days on the Global Market.
- Grace Period: Upon transfer to the Capital Market, the Company received a new 180-calendar day grace period (until January 8, 2024) to regain compliance with the $1.00 minimum bid price.
Outlook, Risks, and Management Commentary
- Compliance Strategy: Management intends to implement a reverse stock split, previously approved by stockholders on June 6, 2023, to regain compliance with the minimum bid price requirement.
- Delisting Risk: If the stock price does not reach $1.00 for at least ten consecutive business days by January 8, 2024, the stock is subject to delisting.
- Contingency: In the event of delisting, the Company may appeal to a Nasdaq Hearings Panel. If the appeal fails, the stock may trade on the OTC Bulletin Board or other small trading markets (e.g., pink sheets).
- Market Differences: The Nasdaq Capital Market has less stringent listing requirements than the Global Market but still requires compliance with specific financial and corporate governance standards.
Investor Verification Checklist
- Verify the current trading symbol (AGLE) and confirm the stock is now listed on The Nasdaq Capital Market.
- Monitor the stock price to ensure it meets the $1.00 minimum bid price for ten consecutive days before the January 8, 2024 deadline.
- Confirm the execution date and ratio of the reverse stock split approved on June 6, 2023.
- Review subsequent filings for any updates on the appeal process or potential delisting notices if the grace period expires without compliance.